| Literature DB >> 35448799 |
Siwar Ghannay1, Kaïss Aouadi1,2, Adel Kadri3,4, Mejdi Snoussi5,6.
Abstract
The main objectives of the present study were to investigate anti-Vibrio spp., antibiofilms, and anti-quorum-sensing (anti-QS) properties of caraway essential oil in relation to their phytochemical composition. The results obtained show the identification of twelve compounds, with carvone (58.2%) and limonene (38.5%) being the main ones. The obtained essential oil (EO) is particularly active against all Vibrio spp. species, with bacteriostatic action against all tested strains (MBC/MIC ratio ≥ 4) and with inhibition zones with high diameters of growth, ranging from 8.66 ± 0.58 mm for V. furnisii ATCC 35016 to 37.33 ± 0.58 mm for V. alginolyticus ATCC 17749. Caraway essential oil (Carvone/limonene chemotype) exhibits antioxidant activities by using four tests (DPPH = 15 ± 0.23 mg/mL; reducing power = 7.8 ± 0.01 mg/mL; β-carotene = 3.9 ± 0.025 mg/mL; chelating power = 6.8 ± 0.05 mg/mL). This oil is particularly able to prevent cell-to-cell communication by inhibiting swarming motility, production of elastase and protease in Pseudomonas aeruginosa PAO1, and violacein production in C. violaceum in a concentration-dependent manner. A molecular docking approach shows good interaction of the identified bioactive molecules in caraway EO, with known target enzymes involved in antioxidant, antibacterial, and anti-QS activities having high binding energy. Overall, the obtained results highlight the possible use of caraway essential oil against pathogenic Vibrio species and to attenuate the secretion of virulence-related factors controlled by QS systems in Gram-negative bacteria. Therefore, this oil can be used by food industries to prevent biofilm formation on abiotic surfaces by Vibrio strains.Entities:
Keywords: Carum carvi L.; Vibrio spp.; anti-quorum sensing; antioxidant; biofilm; molecular docking; pharmacokinetics; volatile oil
Year: 2022 PMID: 35448799 PMCID: PMC9032858 DOI: 10.3390/plants11081072
Source DB: PubMed Journal: Plants (Basel) ISSN: 2223-7747
Chemical composition of Carum carvi L. (seeds) EO. l.r.i.: Linear Retention Index.
| Code | Components | l.r.i. | Percentage | MW (g·mol−1) | Chemical Formula |
|---|---|---|---|---|---|
|
| |||||
|
| Myrcene | 993 | 0.4 | 136.238 | C10H16 |
|
| D-3-carene | 1013 | 0.1 | 136.238 | C10H16 |
|
|
|
|
| 136.238 | C10H16 |
|
| |||||
|
| 1126 | 0.1 | 152.237 | C10H16O | |
|
| 1136 | 0.1 | 152.230 | C10H16O | |
|
| 1139 | 0.1 | 152.230 | C10H16O | |
|
| 1195 | 0.7 | 152.230 | C10H16O | |
|
| 1202 | 0.2 | 152.230 | C10H16O | |
|
| 1219 | 0.1 | 152.230 | C10H16O | |
|
| 1231 | 0.1 | 152.230 | C10H16O | |
|
|
|
|
| 150.220 | C10H14O |
|
| |||||
|
| Eugenol | 1358 | 0.1 | 164.200 | C10H12O2 |
Figure 1Structure of phytocompounds identified by GC-MS technique from caraway essential oil. Legend: (1): Myrcene; (2): D-3-carene; (3): Limonene; (4): trans-p-mentha-2.8-dien-1-ol; (5): cis-limonene oxide; (6): cis-p-mentha-2.8-dien-1-ol; (7): cis-dihydrocarvone; (8): trans-dihydrocarvone; (9): trans-carveol; (10): cis-carveol; (11): Carvone; (12): Eugenol.
Antioxidant activities of caraway essential oil compared to ascorbic acid and BHT. BHT: Butylated hydroxytoluene. The letters (a–c) indicate a significant difference between the different antioxidant methods according to the Duncan test (p < 0.05).
| DPPH | Reducing Power | β-Carotene | Chelating Power | |
|---|---|---|---|---|
|
| 15 ± 0.23 a | 7.8 ± 0.01 c | 3.9 ± 0.025 a | 6.8 ± 0.05 b |
|
| 12 ± 0.01 b | 25 ± 0.01 a | - | - |
|
| 11.5 ± 0.62 b | 23.00 ± 1.0 b | 4.60 ± 1.60 a | - |
|
| - | - | - | 32.50 ± 1.32 a |
Antimicrobial activity of the tested Carum essential oil evaluated by disc diffusion and microdilution assays as compared to five antibiotics. GIZ: Mean of Growth Inhibition Zone. The letters (a–o) indicate a significant difference between the different means of GIZ according to the Duncan test (p < 0.05). C: chloramphenicol 30 µg; AM: ampicillin 10 µg; E: erythromycin 10 µg; TE: tetracycline 5 µg; G: gentamycin 10 µg.
| Microorganisms Tested | Disc Diffusion Assay | Microdilution Assay | |||||||
|---|---|---|---|---|---|---|---|---|---|
| (GIZ ± SD) | C | AM | E | TE | G | MIC | MBC | MBC/MIC Ratio | |
| 23.33 ± 0.58 l | 27 | 8 | 6 | 20 | 18 | 0.022 | 5.781 | >4; Bacteriostatic | |
|
| 11.67 ± 0.58 cd | 8 | 10 | 6 | 21 | 20 | 0.022 | 5.781 | >4; Bacteriostatic |
| 30.33 ± 0.58 n | 17 | 7 | 26 | 24 | 16 | 0.022 | 23.125 | >4; Bacteriostatic | |
|
| 11.33 ± 0.58 c | 18 | 7 | 17 | 13 | 19 | 0.022 | 5.781 | >4; Bacteriostatic |
|
| 13.33 ± 0.58 e | 30 | 6 | 6 | 25 | 20 | 0.022 | 11.562 | >4; Bacteriostatic |
| 16.00 ± 0.00 g | 8 | 7 | 7 | 17 | 17 | 0.022 | 11.562 | >4; Bacteriostatic | |
| 22.66 ± 0.58 l | 22 | 7 | 14 | 17 | 18 | 0.022 | 2.890 | >4; Bacteriostatic | |
| 16.66 ± 0.58 gh | 7 | 7 | 14 | 20 | 16 | 0.022 | 11.562 | >4; Bacteriostatic | |
| 25.33 ± 0.58 m | 19 | 10 | 14 | 15 | 20 | 0.022 | 11.562 | >4; Bacteriostatic | |
|
| 12.66 ± 0.58 de | 24 | 7 | 12 | 14 | 18 | 0.022 | 5.781 | >4; Bacteriostatic |
|
| 11.33 ± 0.58 fg | 13 | 7 | 7 | 13 | 20 | 0.022 | 5.781 | >4; Bacteriostatic |
|
| 11.67 ± 0.58 cd | 13 | 10 | 7 | 15 | 17 | 0.022 | 11.562 | >4; Bacteriostatic |
| 17.66 ± 0.58 h | 22 | 6 | 22 | 17 | 17 | 0.022 | 11.562 | >4; Bacteriostatic | |
| 37.33 ± 0.58 o | 25 | 7 | 7 | 16 | 12 | 0.045 | 2.890 | >4; Bacteriostatic | |
|
| 24.66 ± 0.58 m | 20 | 6 | 20 | 15 | 10 | 0.022 | 11.562 | >4; Bacteriostatic |
|
| 11.67 ± 0.58 cd | 13 | 6 | 7 | 11 | 12 | 0.022 | 2.890 | >4; Bacteriostatic |
|
| 12.67 ± 0.58 de | 29 | 15 | 14 | 7 | 23 | 0.090 | 23.125 | >4; Bacteriostatic |
|
| 22.66 ± 0.58 l | 18 | 8 | 15 | 13 | 20 | 0.022 | 2.891 | >4; Bacteriostatic |
| 8.66 ± 0.58 a | 33 | 7 | 30 | 20 | 13 | 0.022 | 23.125 | >4; Bacteriostatic | |
| 10.33 ± 058 b | 24 | 7 | 30 | 18 | 15 | 0.022 | 23.125 | >4; Bacteriostatic | |
| 20.33 ± 0.58 j | 24 | 8 | 10 | 16 | 16 | 0.022 | 11.562 | >4; Bacteriostatic | |
| 21.67 ± 0.58 k | 18 | 13 | 25 | 16 | 14 | 0.022 | 5.781 | >4; Bacteriostatic | |
| 21.33 ± 0.58 k | 18 | 10 | 12 | 15 | 14 | 0.022 | 11.562 | >4; Bacteriostatic | |
| 14.66 ± 0.58 f | 11 | 7 | 7 | 17 | 18 | 0.022 | 11.562 | >4; Bacteriostatic | |
|
| 23.66 ± 0.58 l | 24 | 6 | 19 | 14 | 20 | 0.045 | 5.781 | >4; Bacteriostatic |
| 14.33 ± 0.58 f | 6 | 10 | 7 | 15 | 17 | 0.022 | 5.781 | >4; Bacteriostatic | |
| 17.66 ± 0.58 h | 27 | 7 | 12 | 16 | 20 | 0.022 | 5.781 | >4; Bacteriostatic | |
| 12.00 ± 0.00 cd | 22 | 8 | 30 | 19 | 18 | 0.022 | 11.562 | >4; Bacteriostatic | |
| 20.00 ± 1.00 ij | 10 | 19 | 6 | 34 | 15 | 0.022 | 11.562 | >4; Bacteriostatic | |
| 19.33 ± 0.58 i | 22 | 6 | 22 | 24 | 16 | 0.022 | 11.562 | >4; Bacteriostatic | |
| 16.66 ± 0.58 gh | 23 | 8 | 7 | 19 | 15 | 0.022 | 11.562 | >4; Bacteriostatic | |
Figure 2Effects of different concentrations of C. carvi EO on biofilm formation (A) and eradication (B) expressed as percentages of inhibition evaluated by the XTT technique: V. alginolyticus ATCC 33787 (1, MIC value = 0.022 mg/mL), V. parahaemolyticus ATCC 17802 (2, MIC value = 0.022 mg/mL), V. vulnificus ATCC 27962 (3, MIC value = 0.022 mg/mL), and V. cholerae ATCC 9459 (4). Errors bars represent standard deviation. Values are the average of at least three independent determinations. Means followed by the same letters are not significantly different at p < 0.05 based on Duncan’s multiple range test. Small letters are used to compare different concentrations within the same strain, and capital letters are used to compare means between the same concentrations between strains.
Effect of caraway essential oil and its major compound (carvone) on the swarming activity of P. aeruginosa PAO1 strain expressed as mean diameter of growth on LB-0.5% agar (mm).
| Control | Concentrations Tested (mg/mL) | |||||
|---|---|---|---|---|---|---|
| 2.5 | 1.25 | 0.625 | 0.5 | 0.05 | ||
|
| 54.00 ± 0.00 | 11.33 ± 0.57 | 13.33 ± 0.57 | 15.66 ± 0.57 | 16.00 ± 0.00 | 17.33 ± 1.15 |
|
| 54.00 ± 0.00 | 11.00 ± 0.00 | 11.66 ± 0.57 | 13.00 ± 0.00 | 14.33 ± 0.57 | 15.66 ± 0.57 |
Figure 3Effect of caraway essential oil and its main compound (Carvone) tested at different concentrations on P. aeruginosa PAO1 (virulence-related properties controlled by quorum-sensing system: (A) proteolytic activity; (B) elastolytic activity). Values are the average of at least three independent determinations. Means followed by the same letters are not significantly different at p < 0.05 based on Duncan’s multiple range test.
Figure 4(A) Effect of caraway essential oil on violacein production by C. violaceum CV026 tested on Lauria–Bertani agar as compared to limonene at 2 mg/disc (B).
Inhibition of violacein production by C. violaceum ATCC 12472 by caraway essential oil at different MIC values. The letters (a,b) indicate significant difference according to the Duncan test (p < 0.05).
| Concentration Tested | % of Violacein Inhibition |
|---|---|
| MIC; (10 mg/mL) | 47.57 ± 3.7 a |
| MIC/2; (5 mg/mL) | 32.26 ± 2.2 b |
| MIC/4; (2.5 mg/mL) | 29.17 ± 1.3 b |
| MIC/8; (1.25 mg/mL) | 28.21 ± 6.1 b |
| MIC/16; (0.625 mg/mL) | 27.89 ± 6.0 b |
| MIC/32; (0.312 mg/mL) | 25.28 ± 4.3 b |
Figure 5Two-dimensional (2D) and three-dimensional (3D) residual interactions network of eugenol (A,B), trans-dihydrocarvone (C,D), and trans-carveol (E,F) with the active site of tyrosyl-tRNA synthetase (PDB Id: 1JIJ) enzyme.
Figure 6Two-dimensional (2D) and three-dimensional (3D) residual interactions network of carvone (A,B) and cis-carveol (C,D) with the active site of topoisomerase II DNA gyrase (PDB Id: 2XCT) enzyme.
Figure 7Two-dimensional (2D) and three-dimensional (3D) residual interactions network of trans-p-mentha-2.8-dien-1-ol (A,B) with the active site of Human peroxiredoxin 5 (PDB ID: 1HD2) enzyme.
Figure 8Two-dimensional (2D) and three-dimensional (3D) residual interactions network of trans-carveol (A,B) and limonene (C,D) with the active site of LasR enzyme (PDB ID, 2UV0).
Figure 9Two-dimensional (2D) and three-dimensional (3D) residual interactions network of carvone (A,B) and trans-dihydrocarvone (C,D) with the active site of LasR enzyme (PDB ID, 3IX3).
Figure 10Two-dimensional (2D) and three-dimensional (3D) residual interactions network of carvone (A,B), and limonene (C,D) with the active site of CviR enzyme (PDB ID, 3QP1).
Best phytoconstituents with the lowest binding energies and their interaction residues with selected target proteins.
| Compounds | Interacting Residues | Binding Energy |
|---|---|---|
| −5.2 | ||
| −6.3 | ||
| −6.4 | ||
| Eugenol vs. IJIJ | −6.3 | |
| −5.3 | ||
| Carvone vs. 2XCT | −5.3 | |
| Limonene vs. 2UV0 | −7.4 | |
| −7.5 | ||
| Carvone vs. 3IX3 | −7.5 | |
| −7.5 | ||
| Limonene vs. 3QP1 | −7.4 | |
| Carvone vs. 3QP1 | −7.5 |
ADMET properties of the identified compounds from caraway essential oil. Compounds 1–12 are the same as those listed in Table 1.
| ADMET Predicted Profile | 1 | 2 | 3 | 4 | ||||
|---|---|---|---|---|---|---|---|---|
| Results | Probability | Results | Probability | Results | Probability | Results | Probability | |
|
| ||||||||
| Human Intestinal Absorption | + | 0.9698 | + | 0.9819 | + | 0.9692 | + | 0.9795 |
| Caco-2 Permeability | + | 0.7783 | + | 0.7793 | + | 0.7994 | + | 0.6792 |
| Blood–Brain Barrier | + | 0.9967 | + | 0.9911 | + | 0.9962 | + | 0.9564 |
| Human oral bioavailability | - | 0.5286 | + | 0.8000 | + | 0.6143 | - | 0.6286 |
| Subcellular localization | Nucleus | 0.5972 | Lysosomes | 0.7499 | Lysosomes | 0.6471 | Lysosomes | 0.5661 |
| P-glycoprotein inhibitor | - | 0.9810 | - | 0.9663 | - | 0.9834 | - | 0.9846 |
| P-glycoprotein substrate | - | 0.9692 | - | 0.9250 | - | 0.9317 | - | 0.8969 |
|
| ||||||||
| CYP3A4 substrate | - | 0.6665 | - | 0.5787 | - | 0.6282 | - | 0.5108 |
| CYP2C9 substrate | - | 0.8209 | - | 0.7890 | - | 0.8110 | - | 0.7759 |
| CYP2D6 substrate | - | 0.7550 | - | 0.7441 | - | 0.7415 | - | 0.7764 |
| CYP3A4 inhibition | - | 0.9747 | - | 0.8365 | - | 0.9257 | - | 0.7643 |
| CYP2C9 inhibition | - | 0.9178 | - | 0.7654 | - | 0.9308 | - | 0.8692 |
| CYP2C19 inhibition | - | 0.8849 | - | 0.7419 | - | 0.8906 | - | 0.8058 |
| CYP2D6 inhibition | - | 0.9341 | - | 0.9171 | - | 0.9398 | - | 0.9189 |
| CYP1A2 inhibition | - | 0.7790 | - | 0.7877 | - | 0.7497 | - | 0.8169 |
| CYP inhibitory promiscuity | - | 0.7215 | - | 0.7928 | - | 0.7657 | - | 0.9195 |
|
| ||||||||
| Carcinogenicity | + | 0.5429 | - | 0.7571 | - | 0.4589 | - | 0.7857 |
| Ames mutagenesis | - | 0.9200 | - | 0.8700 | - | 1.0000 | - | 0.8600 |
| Human ether-a-go-go inhibition | - | 0.6620 | - | 0.4935 | - | 0.5586 | - | 0.5665 |
| Micronuclear | - | 0.9900 | - | 0.9200 | - | 1.0000 | - | 0.9700 |
| Hepatotoxicity | - | 0.8250 | - | 0.8250 | - | 0.8250 | - | 0.8000 |
| Acute Oral Toxicity | III | 0.8030 | III | 0.8186 | III | 0.9069 | III | 0.8083 |
| Biodegradation | + | 0.9000 | + | 0.5500 | + | 0.9500 | + | 0.8000 |
|
| ||||||||
| Water solubility | −3.443 | −4.227 | −3.937 | −1.609 | ||||
| Plasma protein binding | 0.433 | 0.837 | 0.373 | 0.555 | ||||
| Acute Oral Toxicity | 1.66 | 1.5 | 1.856 | 3.839 | ||||
|
| 1.193 | 0.252 | 0.113 | −0.445 | ||||
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
| |
|
| ||||||||
| Human Intestinal Absorption | + | 0.9840 | + | 0.9795 | + | 0.9873 | + | 0.9873 |
| Caco-2 Permeability | + | 0.7132 | + | 0.6792 | + | 0.7226 | + | 0.7226 |
| Blood–Brain Barrier | + | 0.9743 | + | 0.9564 | + | 0.9778 | + | 0.9778 |
| Human oral bioavailability | + | 0.7000 | - | 0.6286 | + | 0.6286 | + | 0.6286 |
| Subcellular localization | Lysosomes | 0.5804 | Lysosomes | 0.5661 | Mitochondria | 0.5743 | Mitochondria | 0.5743 |
| P-glycoprotein inhibitor | - | 0.9840 | - | 0.9846 | - | 0.9772 | - | 0.9772 |
| P-glycoprotein substrate | - | 0.9223 | - | 0.8969 | - | 0.9097 | - | 0.9097 |
|
| ||||||||
| CYP3A4 substrate | + | 0.5411 | - | 0.5108 | - | 0.6066 | - | 0.6066 |
| CYP2C9 substrate | - | 1.0000 | - | 0.7759 | - | 0.8012 | - | 0.8012 |
| CYP2D6 substrate | - | 0.7083 | - | 0.7764 | - | 0.7855 | - | 0.7855 |
| CYP3A4 inhibition | - | 0.8418 | - | 0.7643 | - | 0.9166 | - | 0.9166 |
| CYP2C9 inhibition | - | 0.5512 | - | 0.8692 | - | 0.9518 | - | 0.9518 |
| CYP2C19 inhibition | + | 0.5571 | - | 0.8058 | - | 0.8753 | - | 0.8753 |
| CYP2D6 inhibition | - | 0.9316 | - | 0.9189 | - | 0.9395 | - | 0.9395 |
| CYP1A2 inhibition | + | 0.7089 | - | 0.8169 | - | 0.7044 | - | 0.7044 |
| CYP inhibitory promiscuity | - | 0.8628 | - | 0.9195 | - | 0.8829 | - | 0.8829 |
|
| ||||||||
| Carcinogenicity | - | 0.8857 | - | 0.7857 | - | 0.7857 | - | 0.7857 |
| Ames mutagenesis | - | 0.9000 | - | 0.8600 | - | 0.8200 | - | 0.8200 |
| Human ether-a-go-go inhibition | - | 0.5581 | - | 0.5665 | - | 0.7524 | - | 0.7524 |
| Micronuclear | - | 0.8100 | - | 0.9700 | - | 1.0000 | - | 1.0000 |
| Hepatotoxicity | - | 0.7500 | - | 0.8000 | - | 0.8500 | - | 0.8500 |
| Acute Oral Toxicity | III | 0.8102 | III | 0.8083 | III | 0.8245 | III | 0.8245 |
| Biodegradation | + | 0.6000 | + | 0.8000 | + | 0.8500 | + | 0.8500 |
|
| ||||||||
| Water solubility | −2.724 | −1.609 | −2.117 | −2.117 | ||||
| Plasma protein binding | 0.589 | 0.555 | 0.394 | 0.394 | ||||
| Acute Oral Toxicity | 1.438 | 3.839 | 2.061 | 2.061 | ||||
|
| 0.762 | −0.445 | 0.236 | 0.236 | ||||
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
| |
|
| ||||||||
| Human Intestinal Absorption | + | 0.9859 | + | 0.9859 | + | 0.9956 | + | 0.9767 |
| Caco-2 Permeability | + | 0.7041 | + | 0.7041 | + | 0.7047 | + | 0.6118 |
| Blood–Brain Barrier | + | 0.9406 | + | 0.9406 | + | 0.9791 | + | 0.9260 |
| Human oral bioavailability | + | 0.5714 | + | 0.5714 | + | 0.5714 | - | 0.5857 |
| Subcellular localization | Mitochondria | 0.4869 | Mitochondria | 0.4869 | Mitochondria | 0.6420 | Mitochondria | 0.7362 |
| P-glycoprotein inhibitor | - | 0.9772 | - | 0.9772 | - | 0.9716 | - | 0.9765 |
| P-glycoprotein substrate | - | 0.8702 | - | 0.8702 | - | 0.9360 | - | 0.8741 |
|
| ||||||||
| CYP3A4 substrate | - | 0.6433 | - | 0.6433 | - | 0.6171 | + | 0.5312 |
| CYP2C9 substrate | - | 0.8090 | - | 0.8090 | - | 0.8078 | - | 1.0000 |
| CYP2D6 substrate | - | 0.7021 | - | 0.7021 | - | 0.8631 | - | 0.6817 |
| CYP3A4 inhibition | - | 0.8309 | - | 0.8309 | - | 0.8964 | - | 0.9404 |
| CYP2C9 inhibition | - | 0.9206 | - | 0.9206 | - | 0.9425 | - | 0.9581 |
| CYP2C19 inhibition | - | 0.7038 | - | 0.7038 | - | 0.6994 | - | 0.8321 |
| CYP2D6 inhibition | - | 0.8987 | - | 0.8987 | - | 0.9069 | - | 0.9267 |
| CYP1A2 inhibition | - | 0.8306 | - | 0.8306 | - | 0.8146 | - | 0.8382 |
| CYP inhibitory promiscuity | - | 0.8346 | - | 0.8346 | - | 0.8246 | - | 0.9270 |
|
| ||||||||
| Carcinogenicity | - | 0.8571 | - | 0.8571 | - | 0.6768 | - | 0.8429 |
| Ames mutagenesis | - | 0.9500 | - | 0.9500 | - | 0.9600 | - | 0.6300 |
| Human ether-a-go-go inhibition | - | 0.5592 | - | 0.5592 | - | 0.5429 | - | 0.5685 |
| Micronuclear | - | 0.8900 | - | 0.8900 | - | 0.8100 | - | 0.9700 |
| Hepatotoxicity | - | 0.8000 | - | 0.8000 | - | 0.6750 | - | 0.8750 |
| Acute Oral Toxicity | III | 0.8021 | III | 0.8021 | III | 0.8144 | III | 0.7376 |
| Biodegradation | + | 0.7750 | + | 0.7750 | + | 0.6500 | - | 0.5250 |
|
| ||||||||
| Water solubility | −2.258 | −2.258 | −1.998 | −2.874 | ||||
| Plasma protein binding | 0.546 | 0.546 | 0.654 | 0.895 | ||||
| Acute Oral Toxicity | 1.896 | 1.896 | 1.845 | 3.394 | ||||
|
| 0.162 | 0.162 | 0.6 | 0.012 | ||||
Grid size and dimensions for the receptors.
| Protein (PDB ID) | Grid Size | Grid Dimension Center | Grid Spacing in Å |
|---|---|---|---|
| 1HD2 | 40 × 40 × 40 | 7.089, 41.659, 34.385 | 0.375 |
| 1JIJ | 40 × 40 × 40 | −11.273, 13.817, 86.080 | 0.375 |
| 2UV0 | 40 × 40 × 40 | 23.998, 16.050, 80.315 | 0.375 |
| 2XCT | 52 × 52 × 52 | 30.098, 32.836, 89.243 | 0.375 |
| 3IX3 | 52 × 52 × 52 | 14.630, −1.973, 9.690 | 0.375 |
| 3QP1 | 38 × 40 × 40 | 20.546, 12.912, 49.410 | 0.375 |
| 3QPR | 126 × 126 × 126 | 54.057, 84.102, 205.034 | 0.375 |
| 3HIR | 60 × 60 × 60 | −26.388, 13.803, −15.845 | 0.375 |